The history of Viagra and its influence on the pharmaceutical sector presents a challenging question regarding its continued appeal as an investment. Initially a phenomenal success, generating billions , generic competition has significantly eroded earnings . While major pharmaceutical firms maintain patents on related therapies and investigate new
Sildenafil and its Maker and Big Pharma: A Dangerous Investment?
The outlook of companies tied to blockbuster drugs like Viagra presents a complex investment picture. While the initial boom of copyright, fueled by Viagra's remarkable popularity, generated substantial wealth , the expiry in key regions has introduced substantial volatility. Investors are now facing the consequences of rival medications , shrinkin